Drug Profile
Research programme: gene-silencing oligonucleotides - GSK/Aceragen
Alternative Names: Renal disease therapeutics - Aceragen/GSK; Third generation antisense-based therapeutics - GSK/AceragenLatest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen; GlaxoSmithKline
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Renal failure